Another study indicates that RBM3 attenuates the stemness and tumorigenesis of prostate cancer cells by inhibiting CD44 variant splicing [163], although this finding is in contrast to findings in colorectal cancer [169]. This evidence concerns the gene CD44 and prostate carcinoma.